SG165364A1 - Treatment of autoimmune diseases - Google Patents

Treatment of autoimmune diseases

Info

Publication number: SG165364A1
Authority: SG; Singapore
Prior art keywords: autoimmune diseases; treatment; neuritis; uveitis; methods
Prior art date: 2005-09-09

Application number

SG201006580-3A

Other languages

English (en)

Inventor

Rainer Albert

Nigel Graham Cooke

Barbara Nuesslein-Hildesheim

Sven Weiler

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-09

Filing date

2006-09-07

Publication date

2010-10-28

2006-09-07 Application filed by Novartis Ag filed Critical Novartis Ag

2010-10-28 Publication of SG165364A1 publication Critical patent/SG165364A1/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SG201006580-3A 2005-09-09 2006-09-07 Treatment of autoimmune diseases SG165364A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US71599005P	2005-09-09	2005-09-09

Publications (1)

Publication Number	Publication Date
SG165364A1 true SG165364A1 (en)	2010-10-28

Family

ID=37056992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG201006580-3A SG165364A1 (en)	2005-09-09	2006-09-07	Treatment of autoimmune diseases

Country Status (28)

Country	Link
US (1)	US20080200438A1 (ru)
EP (2)	EP2295049B1 (ru)
JP (4)	JP5244598B2 (ru)
KR (3)	KR101476591B1 (ru)
CN (1)	CN101257899B (ru)
AT (1)	ATE489948T1 (ru)
AU (2)	AU2006289100B2 (ru)
BR (1)	BRPI0615906A2 (ru)
CA (2)	CA2820510A1 (ru)
CY (1)	CY1111285T1 (ru)
DE (1)	DE602006018629D1 (ru)
DK (2)	DK1926483T3 (ru)
ES (2)	ES2529724T3 (ru)
IL (2)	IL189665A (ru)
JO (1)	JO2655B1 (ru)
MA (1)	MA29787B1 (ru)
MX (1)	MX2008003170A (ru)
NO (1)	NO20081727L (ru)
NZ (2)	NZ566137A (ru)
PL (2)	PL2295049T3 (ru)
PT (2)	PT2295049E (ru)
RU (2)	RU2493840C2 (ru)
SG (1)	SG165364A1 (ru)
SI (2)	SI2295049T1 (ru)
TN (1)	TNSN08103A1 (ru)
TW (2)	TWI376223B (ru)
WO (1)	WO2007028821A2 (ru)
ZA (1)	ZA200801694B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1772145T1 (sl) *	2004-07-16	2011-06-30	Kyorin Seiyaku Kk	Postopek za učinkovito uporabo zdravila in postopek za preprečevanje stranskih učinkov
PT2511262T (pt)	2004-10-12	2017-03-30	Kyorin Seiyaku Kk	Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
WO2007043433A1 (ja) *	2005-10-07	2007-04-19	Kyorin Pharmaceutical Co., Ltd.	２－アミノ－１，３－プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法
TWI389683B (zh) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
SG174028A1 (en) *	2006-08-08	2011-09-29	Kyorin Seiyaku Kk	Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
SG174029A1 (en) *	2006-08-08	2011-09-29	Kyorin Seiyaku Kk	Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
WO2008099781A1 (ja) *	2007-02-13	2008-08-21	Kyorin Pharmaceutical Co., Ltd.	アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
JP5452237B2 (ja)	2008-02-07	2014-03-26	杏林製薬株式会社	アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
NZ589412A (en) *	2008-05-20	2012-11-30	Kyorin Seiyaku Kk	Use of a sphingosine-1-phosphate (S1P) agonist for maintance of induced remission of autoimmune or inflammatory diseases after inital treatment
CN104892474A (zh) *	2008-08-18	2015-09-09	诺华股份有限公司	用于治疗脱髓鞘性周围神经病的氨基醇衍生物
JP2013530937A (ja) *	2010-05-06	2013-08-01	ノバルティスアーゲー	自己免疫疾患の処置剤
AU2011249789B2 (en) *	2010-05-06	2015-03-19	Novartis Ag	Dosage regimen of diaryl sulfide derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5141421A (en) *	1991-12-17	1992-08-25	Carrier Corporation	Nested coupling mechanism for scroll machines
DE4428835A1 (de) *	1994-08-01	1996-02-08	Schering Ag	Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
ES2317663T3 (es) *	1997-02-27	2009-04-16	Novartis Ag	Composicion farmaceutica que comprende 2-amino-2-(2-(4-octilfenil)etil)propano-1,3-diol, una lecitina y un sacarido.
JP4217620B2 (ja) *	2001-09-27	2009-02-04	杏林製薬株式会社	ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤
CA2460640C (en) *	2001-09-27	2011-03-29	Kyorin Pharmaceutical Co., Ltd.	Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
JP4571497B2 (ja) *	2002-09-19	2010-10-27	杏林製薬株式会社	アミノアルコール誘導体とその付加塩及び免疫抑制剤
RU2391094C2 (ru) *	2002-09-24	2010-06-10	Новартис Аг	Применение агониста рецептора s1p и способ лечения, облегчения или задержки прогрессирования неврита зрительного нерва или демиелинизационных заболеваний
WO2004028504A1 (en) *	2002-09-28	2004-04-08	Mcneil-Ppc, Inc.	Modified release dosage forms
AU2004213297B2 (en) *	2003-02-18	2009-03-19	Kyorin Pharmaceutical Co., Ltd.	Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators
GB2400318B (en) *	2003-04-08	2005-08-10	Novartis Ag	Pharmaceutical composition comprising an S1P receptor agonist
WO2005014525A2 (en) *	2003-08-12	2005-02-17	Mitsubishi Pharma Corporation	Bi-aryl compound having immunosuppressive activity
EP1660449B1 (en) *	2003-08-28	2009-11-18	Novartis AG	Aminopropanol derivatives
SI1772145T1 (sl) *	2004-07-16	2011-06-30	Kyorin Seiyaku Kk	Postopek za učinkovito uporabo zdravila in postopek za preprečevanje stranskih učinkov
KR20130041385A (ko) *	2004-11-29	2013-04-24	노파르티스 아게	Ｓ１ｐ 수용체 효능제의 투여 용법
GB0504544D0 (en) *	2005-03-04	2005-04-13	Novartis Ag	Organic compounds

2006
- 2006-09-07 RU RU2011111117/15A patent/RU2493840C2/ru not_active IP Right Cessation
- 2006-09-07 SG SG201006580-3A patent/SG165364A1/en unknown
- 2006-09-07 KR KR1020147001496A patent/KR101476591B1/ko not_active Expired - Fee Related
- 2006-09-07 ES ES10174280.7T patent/ES2529724T3/es active Active
- 2006-09-07 US US12/065,096 patent/US20080200438A1/en not_active Abandoned
- 2006-09-07 ES ES06793341T patent/ES2357426T3/es active Active
- 2006-09-07 BR BRPI0615906-0A patent/BRPI0615906A2/pt not_active IP Right Cessation
- 2006-09-07 PL PL10174280T patent/PL2295049T3/pl unknown
- 2006-09-07 AU AU2006289100A patent/AU2006289100B2/en not_active Ceased
- 2006-09-07 SI SI200631889T patent/SI2295049T1/sl unknown
- 2006-09-07 SI SI200630937T patent/SI1926483T1/sl unknown
- 2006-09-07 DK DK06793341.6T patent/DK1926483T3/da active
- 2006-09-07 DK DK10174280.7T patent/DK2295049T3/en active
- 2006-09-07 CA CA2820510A patent/CA2820510A1/en not_active Abandoned
- 2006-09-07 EP EP10174280.7A patent/EP2295049B1/en not_active Not-in-force
- 2006-09-07 PL PL06793341T patent/PL1926483T3/pl unknown
- 2006-09-07 NZ NZ566137A patent/NZ566137A/en not_active IP Right Cessation
- 2006-09-07 EP EP06793341A patent/EP1926483B1/en active Active
- 2006-09-07 KR KR1020147026128A patent/KR20140117704A/ko not_active Ceased
- 2006-09-07 JP JP2008529636A patent/JP5244598B2/ja active Active
- 2006-09-07 WO PCT/EP2006/066150 patent/WO2007028821A2/en not_active Ceased
- 2006-09-07 CN CN2006800328984A patent/CN101257899B/zh not_active Expired - Fee Related
- 2006-09-07 PT PT10174280T patent/PT2295049E/pt unknown
- 2006-09-07 NZ NZ588372A patent/NZ588372A/en not_active IP Right Cessation
- 2006-09-07 CA CA2620554A patent/CA2620554C/en not_active Expired - Fee Related
- 2006-09-07 AT AT06793341T patent/ATE489948T1/de active
- 2006-09-07 PT PT06793341T patent/PT1926483E/pt unknown
- 2006-09-07 RU RU2008113187/15A patent/RU2424795C2/ru not_active IP Right Cessation
- 2006-09-07 MX MX2008003170A patent/MX2008003170A/es active IP Right Grant
- 2006-09-07 DE DE602006018629T patent/DE602006018629D1/de active Active
- 2006-09-07 JO JO2006298A patent/JO2655B1/en active
- 2006-09-08 TW TW095133326A patent/TWI376223B/zh active
- 2006-09-08 TW TW099117063A patent/TWI372620B/zh not_active IP Right Cessation
2008
- 2008-02-21 IL IL189665A patent/IL189665A/en not_active IP Right Cessation
- 2008-02-21 ZA ZA200801694A patent/ZA200801694B/xx unknown
- 2008-03-06 TN TNP2008000103A patent/TNSN08103A1/en unknown
- 2008-03-17 MA MA30758A patent/MA29787B1/fr unknown
- 2008-04-07 NO NO20081727A patent/NO20081727L/no not_active Application Discontinuation
- 2008-04-08 KR KR1020087008413A patent/KR101476451B1/ko not_active Expired - Fee Related
2010
- 2010-09-21 AU AU2010224355A patent/AU2010224355B2/en not_active Ceased
2011
- 2011-03-01 CY CY20111100242T patent/CY1111285T1/el unknown
2012
- 2012-10-17 JP JP2012230044A patent/JP6077265B2/ja not_active Expired - Fee Related
2014
- 2014-06-23 IL IL233328A patent/IL233328A0/en unknown
- 2014-09-29 JP JP2014199069A patent/JP2015025002A/ja not_active Withdrawn
2016
- 2016-09-30 JP JP2016193400A patent/JP2017019854A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CA2820510A1 (en)	2007-03-15
DE602006018629D1 (de)	2011-01-13
RU2493840C2 (ru)	2013-09-27
KR101476591B1 (ko)	2014-12-24
US20080200438A1 (en)	2008-08-21
ATE489948T1 (de)	2010-12-15
JP2009507810A (ja)	2009-02-26
NO20081727L (no)	2008-06-06
MA29787B1 (fr)	2008-09-01
TWI372620B (en)	2012-09-21
DK2295049T3 (en)	2015-02-23
JP5244598B2 (ja)	2013-07-24
IL233328A0 (en)	2014-08-31
AU2010224355A1 (en)	2010-10-14
JP2015025002A (ja)	2015-02-05
TNSN08103A1 (en)	2009-07-14
WO2007028821A3 (en)	2007-05-03
KR101476451B1 (ko)	2014-12-24
TW201034659A (en)	2010-10-01
AU2010224355B2 (en)	2012-03-29
EP2295049B1 (en)	2014-11-26
JP6077265B2 (ja)	2017-02-08
JP2013010802A (ja)	2013-01-17
JP2017019854A (ja)	2017-01-26
EP2295049A1 (en)	2011-03-16
RU2424795C2 (ru)	2011-07-27
AU2006289100A1 (en)	2007-03-15
IL189665A0 (en)	2008-06-05
NZ588372A (en)	2012-03-30
AU2006289100B2 (en)	2010-07-22
CA2620554C (en)	2013-12-17
PL2295049T3 (pl)	2015-04-30
PT2295049E (pt)	2015-03-02
EP1926483B1 (en)	2010-12-01
SI1926483T1 (sl)	2011-04-29
ZA200801694B (en)	2009-09-30
MX2008003170A (es)	2008-03-18
CN101257899B (zh)	2012-10-03
IL189665A (en)	2014-07-31
CN101257899A (zh)	2008-09-03
TW200803829A (en)	2008-01-16
SI2295049T1 (sl)	2015-03-31
WO2007028821A2 (en)	2007-03-15
JO2655B1 (en)	2012-06-17
KR20140019033A (ko)	2014-02-13
CA2620554A1 (en)	2007-03-15
NZ566137A (en)	2011-05-27
PT1926483E (pt)	2011-03-03
HK1149906A1 (en)	2011-10-21
KR20140117704A (ko)	2014-10-07
RU2008113187A (ru)	2009-10-20
ES2529724T3 (es)	2015-02-25
DK1926483T3 (da)	2011-03-14
PL1926483T3 (pl)	2011-05-31
EP1926483A2 (en)	2008-06-04
CY1111285T1 (el)	2015-08-05
TWI376223B (en)	2012-11-11
KR20080046231A (ko)	2008-05-26
ES2357426T3 (es)	2011-04-26
RU2011111117A (ru)	2012-09-27
BRPI0615906A2 (pt)	2011-05-31

Publication	Publication Date	Title
TNSN08103A1 (en)	2009-07-14	Treatment of autoimmune diseases
TW200509892A (en)	2005-03-16	Novel aminobenzophenone compounds
SG149063A1 (en)	2009-01-29	Use of modified cyclosporins for the treatment of hcv disorders
MX2007000490A (es)	2007-06-11	Analogos de tetrapeptido.
GB0318447D0 (en)	2003-09-10	Therapeutic agents
EA200601074A1 (ru)	2006-10-27	Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
TW200700422A (en)	2007-01-01	Compounds for inhibiting ksp kinesin activity
UA90698C2 (en)	2010-05-25	Triazole substituted aminobenzophenone compounds
TW200504402A (en)	2005-02-01	Antimicrobial lenses, processes to prepare them and methods of their use
TW200700066A (en)	2007-01-01	Compounds for inhibiting ksp kinesin activity
MXPA06004308A (es)	2006-06-05	Isopentilcarboxanilidas para la lucha contra los microorganismos indeseables.
WO2006078576A3 (en)	2006-10-05	Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
MX2008001428A (es)	2008-04-04	Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
TW200744567A (en)	2007-12-16	Phenylethylamine analogs and their use for treating glaucoma
GB0326633D0 (en)	2003-12-17	Therapeutic agents
TW200738143A (en)	2007-10-16	Use of arylanilides for seed treatment
MXPA06002315A (es)	2006-05-22	Abridores de canal erg para el tratamiento de arritmias cardiacas.
TW200716132A (en)	2007-05-01	Novel chemical compounds
ZA200609220B (en)	2009-02-25	Method of treating dry eye disorders and uveitis
TW200716579A (en)	2007-05-01	Novel chemical compounds
WO2004056762A3 (en)	2004-08-12	Novel aminobenzophenone compounds
UA85198C2 (ru)	2009-01-12	Производные морфолина как ингибиторы повторного поглощения норэпинефрина
TW200714284A (en)	2007-04-16	Novel method
MXPA05009696A (es)	2005-10-20	Procedimiento para producir 1-aril- y 1-heteroaril-2-aminoetanoles enantiomericamente enriquecidos.
TW200628453A (en)	2006-08-16	Triazole substituted aminobenzophenone compounds